#$%^&*AU2020203497A120200618.pdf#####Abstract Provided are pharmaceutical compositions and dosage forms of 2-(tert-butylamino)-4((IR,3R,4R)-3-hydroxy-4- methylcyclohexylamino)-pyrimidine-5-carboxamide, or a pharmaceutically acceptable stereoisomer, tautomer, solid form, poly- morph, salt, hydrate, clathrate, or solvate thereof. Also provided are methods of treating, managing, or preventing various disorders, such as diseases or disorders treatable or preventable by inhibition of a INK pathway in mammals using such pharmaceutical com - positions or dosage forms. Further provided are salts of 2-(tert-butylamino)-4-((IR,3R,4R)-3-hydroxy-4-methylcyclohexylamino)pyrimidine-5-carboxamide and methods of preparation of such salts.
